Detalles de la búsqueda
1.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Breast Cancer Res Treat
; 204(2): 237-248, 2024 Apr.
Artículo
Inglés
| MEDLINE | ID: mdl-38112922
2.
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Gynecol Oncol
; 172: 121-129, 2023 05.
Artículo
Inglés
| MEDLINE | ID: mdl-37030280
3.
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
Br J Cancer
; 120(6): 579-586, 2019 03.
Artículo
Inglés
| MEDLINE | ID: mdl-30783204
4.
Delays in diagnosis and treatment of breast cancer: a multinational analysis.
Eur J Public Health
; 24(5): 761-7, 2014 Oct.
Artículo
Inglés
| MEDLINE | ID: mdl-24029456
5.
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
J Thorac Oncol
; 18(1): 106-119, 2023 01.
Artículo
Inglés
| MEDLINE | ID: mdl-36240972
6.
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
Invest New Drugs
; 30(3): 1216-23, 2012 Jun.
Artículo
Inglés
| MEDLINE | ID: mdl-21594619
7.
The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC.
Clin Breast Cancer
; 22(3): 223-234, 2022 04.
Artículo
Inglés
| MEDLINE | ID: mdl-34844889
8.
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Radiol Oncol
; 56(2): 238-247, 2022 05 17.
Artículo
Inglés
| MEDLINE | ID: mdl-35575587
9.
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG).
Breast Cancer Res Treat
; 119(1): 169-76, 2010 Jan.
Artículo
Inglés
| MEDLINE | ID: mdl-19768533
10.
Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.
Biosci Trends
; 14(1): 48-55, 2020 Mar 16.
Artículo
Inglés
| MEDLINE | ID: mdl-32023563
11.
Therapy of small cell lung cancer with emphasis on oral topotecan.
Lung Cancer
; 70(1): 7-13, 2010 Oct.
Artículo
Inglés
| MEDLINE | ID: mdl-20576312
12.
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.
Wien Klin Wochenschr
; 122(11-12): 368-79, 2010 Jun.
Artículo
Inglés
| MEDLINE | ID: mdl-20549373
Resultados
1 -
12
de 12
1
Próxima >
>>